- Acta en el metabolismo de las grasas
leads the oral GLP-1 market due to a large diabetic and obese population, strong R&D capabilities, and rapid adoption of innovative therapies like oral semaglutide
The Nuclear factor erythroid 2 like 2 ( NFE2L2 ) gene, encoding NRF2 protein, was cloned as a factor that binds to the -globin promoter [139, 140]
Orlistat and empagliflozin were selected as negative controls based on their similarity in the population indicated for GLP-1RAs, without any reported evidence of self-harm or suicide potential in the specification or related studies
In vitro experiments demonstrated that glutamate induced the enhanced levels of FTL, GPX4, and SLC7A11 in R28 cells, which were reversed through the administration of the inhibitor of p38 mitogen-activated protein kinase (MAPK) pathway (102)